IMIain S. MacPherson

Iain S. MacPherson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Iain S. MacPherson has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Noah Soxpollard

    Department of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii, Honolulu, USA

    2 shared publications
  • Albert To

    Hawaii Center for AIDS (HICFA), Department of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii, Honolulu, Hawaii, 96813, USA

    1 shared publication
  • Albert To

    Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii, Manoa, HI, USA

    1 shared publication
  • Axel T. Lehrer

    Hawaii Center for AIDS (HICFA), Department of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii, Honolulu, Hawaii, 96813, USA

    1 shared publication
  • Axel T. Lehrer

    University of Hawaii at Manoa

    1 shared publication
  • Brien K Haun

    University of Hawai

    1 shared publication

Latest Publications

  • Open Access

    Divalent HIV-1 gp120 Immunogen Exhibits Selective Avidity for Broadly Neutralizing Antibody VRC01 Precursors

    by Ryan Bailey, Kalista Kahoekapu, Albert To, Ludwig I. Mayerlen, Helmut Kae, Gabriel Manninen, Brien K. Haun, John M. Berestecky, Cecilia Shikuma, Axel T. Lehrer, et al.

    Background: A major goal for the vaccine field is the elicitation of broadly neutralizing antibodies (bnAbs) against pathogens that exhibit extensive antigenic diversity. Methods: In this study, we designed a rigid divalent immunogen for high avidity binding to the bnAb, VRC01, which targets the CD4 binding site (CD4bs) of the HIV spike protein. This was accomplished by covalently linking two HIV-1 gp120 antigens to a complementary antibody and crosslinking the light chains. Binding kinetics were analyzed using a novel gel shift assay and surface plasmon resonance. Results: The rigid divalent immunogen exhibits a higher affinity for VRC01-class antibodies compared to a flexible control, likely due to antigen pre-organization limiting the entropic penalty for divalent binding. Crucially, this immunogen exhibited divalent binding to VRC01 and monovalent binding to a non-CD4bs Ab, A32—a characteristic we refer to as “selective avidity.” Conclusions: In light of these results, we are preparing for in vivo vaccination experiments to test the immune focusing properties of this immunogen, the results of which may suggest broad application of the selective avidity concept.

  • Open Access

    Divalent HIV-1 gp120 Immunogen Exhibits Selective Avidity for Broadly Neutralizing Antibody VRC01 Precursors

    by Ryan Bailey, Kalista Kahoekapu, Albert To, Ludwig I. Mayerlen, Helmut Kae, Gabriel Manninen, Brien K Haun, John Berestecky, Cecilia Shikuma, Axel T. Lehrer, et al.

    A major goal for the vaccine field is elicitation of broadly neutralizing antibodies (bnAbs) against pathogens that exhibit extensive antigenic diversity. In this study, we designed a rigid divalent immunogen for high avidity binding to the bnAb, VRC01, which targets the CD4 binding site (CD4bs) of HIV spike protein. This was accomplished by covalently linking two HIV-1 gp120 antigens to a complementary antibody and crosslinking the light chains. The divalent immunogen exhibits a higher affinity for VRC01-class antibodies compared to a non-Fab-Fab-crosslinked control, likely due to antigen pre-organization limiting the entropic penalty for divalent binding. Importantly, this immunogen exhibited divalent binding to VRC01 and monovalent binding to a non-CD4bs Ab, A32 - a characteristic we refer to as “selective avidity.” This report supports future in vivo vaccination experiments to test the immune focusing properties of this immunogen, the results of which may suggest broad application of the selective avidity concept. Highlights: - We designed a rigid divalent immunogen containing two copies of gp120 antigen - The gp120s are positioned to bind divalently to both Fabs of a target B cell receptor - The immunogen binds monovalently to non-target B cell receptors - This “selective avidity” effect may be used for immune focusing Graphical

  • Open Access

    Selection of antibody-binding covalent aptamers

    by Noah Soxpollard, Sebastian Strauss, Ralf Jungmann, Iain S. MacPherson

    Aptamers are oligonucleotides with antibody-like binding function, selected from large combinatorial libraries. In this study, we modified a DNA aptamer library with N-hydroxysuccinimide esters, enabling covalent conjugation with cognate proteins. We selected for the ability to bind to mouse monoclonal antibodies, resulting in the isolation of two distinct covalent binding motifs. The covalent aptamers are specific for the Fc region of mouse monoclonal IgG1 and are cross-reactive with mouse IgG2a and other IgGs. Investigation into the covalent conjugation of the aptamers revealed a dependence on micromolar concentrations of Cu2+ ions which can be explained by residual catalyst remaining after modification of the aptamer library. The aptamers were successfully used as adapters in the formation of antibody-oligonucleotide conjugates (AOCs) for use in detection of HIV protein p24 and super-resolution imaging of actin. This work introduces a new method for the site-specific modification of native monoclonal antibodies and may be useful in applications requiring AOCs or other antibody conjugates.


  • Open Access

    Selection of antibody-binding covalent aptamers

    by Noah Soxpollard, Sebastian Strauss, Ralf Jungmann, Iain MacPherson

    Aptamers are oligonucleotides with antibody-like binding function, selected from large combinatorial libraries. In this study, we modified a DNA aptamer library with N-hydroxysuccinimide esters, enabling covalent reactivity with cognate proteins. We selected for the ability to bind to mouse monoclonal antibodies, resulting in the isolation of two distinct covalent binding motifs. The covalent aptamers are specific for the Fc region of mouse monoclonal IgG1 and are cross-reactive with mouse IgG2a and other IgGs. Investigation into the covalent reactivity of the aptamers revealed a dependence on micromolar concentrations of Cu 2+ ions which can be explained by residual catalyst remaining after modification of the aptamer library. The aptamers were successfully used as adapters in the formation of antibody-oligonucleotide conjugates (AOCs) for use in detection of HIV protein p24 and super-resolution imaging of actin. This work introduces a new method for the site-specific modification of native monoclonal antibodies and may be useful in applications requiring AOCs or other antibody conjugates.


  • DNA display of folded RNA libraries enabling RNA-SELEX without reverse transcription

    by I. S. MacPherson, J. S. Temme, I. J. Krauss

    A method for the physical attachment of folded RNA libraries to their encoding DNA is presented as a way to circumvent the reverse transcription step during systematic evolution of RNA ligands by exponential enrichment (RNA-SELEX).